Sera and Vaccines

In an effort to protect against potential future global health emergencies, the government of the UK and Moderna have cemented a 10-year partnership for vaccine manufacturing and research.

A multi-year collaboration between BioNTech and the Government of the United Kingdom will see the expansion of the company’s presence in the UK, focusing on areas like cancer immunotherapies and infectious disease vaccines.

South African biopharma company Biovac signs a partnership deal with the International Vaccine Institute to develop and manufacture an oral cholera vaccine for both the African and global market. 

A new method of vaccine technology that employs weakened viruses has been developed to target DNA viruses that reproduce by making copies of their own DNA molecules, utilising a virus with altered DNA to fight against them.

BioNTech, co-developers of one of the first mRNA COVID-19 vaccines, have signed an agreement to create manufacturing hubs in and around the Australian Victoria state in a bid to increase the country’s mRNA manufacturing abilities.

Moderna’s novel bivalent vaccine is the first of its kind to be approved by the UK Medicines and Healthcare Products Regulatory Agency in the fight against the COVID-19 pandemic and SARS-CoV-2 variants.

The company's goal is to design and test new vaccines for novel pathogens within 100 days of a potential pandemic threat 

The $3.3 billion deal will strengthen GSK’s vaccine pipeline. 

Speaking at CPHI North America, Dr Scott Gottlieb shares insights into how the US should prepare for future pandemics by building out vaccine capacities

CDMO's site becomes the first vaccine production facility in South Korea to obtain EU GMP certification, allowing it to ship to Europe

The company will expand multiple facilities in Hyderabad and Bangalore to help reach its target of approximately 700 million doses per year of the COVID-19 vaccine